The implementation of thyroid hormone (T3) or glucagon as lipid-lowering, antidiabetic, and antiobesity agents have not been successful to date because of serious adverse side effects. Using a synthetic hybrid glucagon/T3 conjugate, Finan et al have established a novel therapeutic approach for the reversal of dyslipidemia, obesity, and insulin resistance associated with the metabolic syndrome, ...